Home › Biotechnology
Biotechnology Market Research Reports & Consulting
Market Reports
| Title | Published | Price | TOC Available |
|---|---|---|---|
Live Cell Encapsulation Market by Technique (Dripping (Simple, Electrostatic), Coaxial Airflow, Liquid Jet), Polymer (Alginate, Chitosan, Silica, Cellulose Sulfate), Application (Probiotics, Transplant, Drug Delivery, Research) - Forecast to 2024The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2% during the forecast period. Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management. The major players operating in the live cell encapsulation market are BioTime, Inc. (US), Reed Pacific Pty Ltd. (Australia), Viacyte, Inc. (US), Neurotech Pharmaceuticals, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top five players in the global live cell encapsulation market. Other prominent players operating in this market include Merck KGAA (Germany), Sigilon Therapeutics, Inc. (US), Encapsys, LLC (US), Evonik Industries (Germany), Lycored (Israel), MiKroCaps (Slovenia), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), Sernova Corporation (Canada), and Balchem Corporation (US), among others. |
April 2019 | $ 5650 |
|
Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024The regenerative medicine market is projected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8%. Market growth is largely driven by the rising prevalence of chronic diseases and genetic disorders, growing government investments in regenerative medicine research, and the increasing number of regenerative medicine companies globally.Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US). |
March 2019 | $ 5650 |
|
Cell-based Assay Market by Product (Reagents, Microplates, Cell Lines, Assay Kits, Instruments, Services), Application (Drug Discovery, Research), End User (CROs, Biopharma Companies, Research Institutes), Geography - Global Forecast to 2024The cell-based assays market is projected to reach USD 18.9 billion by 2024 from USD 13.9 billion in 2019, at a CAGR of 6.3%. The growth of this market is majorly driven by the growing preference for cell-based assays, increasing research funding, and the growth in the number of drug discovery activities. However, the high cost of instruments and restrictions on reagent use are the major factors restraining the growth of this market. Thermo Fisher Scientific, Inc. (US), Danaher Corporation (Beckman Coulter, Inc.) (US), Becton, Dickinson and Company (US), GE Healthcare (US), Merck KGaA (Germany), Lonza Group (Switzerland), PerkinElmer, Inc. (US), Charles River Laboratories, Inc. (US), Cell Signaling Technologies (US), Cisbio (US), Cell Biolabs, Inc. (US), and Promega Corporation (US). |
March 2019 | $ 5650 |
|
Reporter Gene Assay Market by Reagents & Assay kits (Luciferase, Green Fluorescent Protein, â-glucuronidase, â-galactosidase), Application (Gene Regulation, Protein Interaction, Cell Signalling Pathways), End Users, Region - Global Forecast to 2024The reporter gene assays market is projected to reach USD 2.6 billion by 2024 from USD 1.6 billion in 2019, at a CAGR of 10.1%. Factors contributing to the growth of this market include increasing funding for cell-based research, growing applications of gene expression, and rising preference for cell-based assays. The prominent players in the reporter gene assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Danaher Corporation (US), Geno Technology (US), Genecopoeia, Inc. (US), InvivoGen (France), PromoCell (Germany), Becton, Dickinson and Company (US), Biotium, Inc. (US), Canvax (Spain), LI-COR, Inc. (US), System Biosciences, LLC (US), Indigo Biosciences, Inc. (US), BioThema (Sweden), Takara Bio Inc (US), BioAssay Systems (US), Cell Biolabs, Inc. (US), BPS Bioscience, Inc (US), Biosynth AG (Switzerland), and Cayman Chemical (US). |
March 2019 | $ 5650 |
|
Genomics Market by Product and Service (Systems & Software, Consumables, Services), Technology (Sequencing, Microarray, PCR), Application (Diagnostic Application, and Precision Medicine), End User (Research Institute) - Global Forecast to 2024The global genomics market is projected to reach USD 35.7 billion by 2024 from USD 18.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Factors such as the rising government funding and growth in the number of genomics projects, decreasing sequencing costs, growing application areas of genomics, and the entry of new players and start-ups in the genomics field are driving the growth of the genomics market. However, the high cost of genomic equipment could limit market growth to a certain extent in the coming years. Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), BGI (China), GE Healthcare (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Oxford Nanopore Technologies (UK) are the key players operating in the genomics market. |
March 2019 | $ 5650 |
|
miRNA Sequencing and Assay Market by Product (Library Preparation, Consumables), Technology (Sequencing By Synthesis, Nanopore, Ion Semiconductor Sequencing), End User (Research Institute, Academia, CRO), Region - Global Forecast To 2024The miRNA sequencing and assays market is projected to reach USD 343 million by 2024 from USD 182 million in 2018, at a CAGR of 11.2%. Growth in this market is driven by factors such as the advantages of miRNA sequencing over other technologies, increasing research funding for genomics, and the decreasing cost of sequencing.Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Germany), Takara Bio (Japan), NEB (UK), and 5 others. |
March 2019 | $ 5650 |
|
Exosome Research Products Market by Product and Services (Kit, Reagent, Instrument, Service), Application (cancer [lung cancer, prostate cancer, breast cancer]), and End User (Hospitals, Academics, Research Institute) - Global Forecast to 2024The global exosome research products market is projected to reach USD 264 million by 2024 from USD 91 million in 2019, at a CAGR of 23.8% during the forecast period. The growth of this market is driven by factors such as the increasing funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures.Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Bio-Techne (US), System Biosciences, LLC. (US), NX Pharmagen (US), Miltenyi Biotec (Germany), AMS Biotechnology (Europe) Limited (UK), NanoSomiX (US), Lonza (Switzerland), and Norgen Biotek Corp. (Canada) |
February 2019 | $ 5650 |
|
Cell Isolation/Cell Separation Market by Product (Reagents, Beads, Centrifuge), Cell Type (Human, Animal), Cell Source (Bone Marrow, Adipose), Technique (Filtration), Application (Cancer), End User (Hospitals, Biotechnology) - Global Forecast to 2024The cell isolation market is projected to grow from USD 5.9 billion in 2019 to USD 13.0 billion by 2024, at a CAGR of 17.2% during the forecast period. Growth in the cell isolation market is mainly driven by the growing government funding for cell-based research, increasing number of patients suffering from cancer and infectious diseases, technological advancements, and the growing focus on personalized medicine. The major players in the cell isolation market are Beckman Coulter (US), Becton Dickinson and Company (US), GE Healthcare (US), Merck KgaA (Germany), Miltenyi Biotec (Germany), pluriSelect (Germany), STEMCELL Technologies Inc. (Canada), Terumo BCT (US), Thermo Fisher Scientific (US), and Bio-Rad Laboratories Inc. (US). |
February 2019 | $ 5650 |
|
Proteomics Market by Instrument (Spectroscopy, Chromatography, Electrophoresis, Microfluidics, X-ray Crystallography), Reagents, Services & Software (Protein Identification, Characterization, Bioinformatics), Application - Global Forecast to 2024The proteomics market is projected to reach USD 38.7 billion by 2024 from USD 19.5 billion in 2019, at a CAGR of 14.7%. Growth in this market is driven by an increase in research activity (especially in the areas of personalized medicine and drug discovery). Other market drivers include increasing pharmaceutical and biotechnology R&D expenditure, government funding for proteomics, and technological advancements. In 2018, North America dominated the global proteomics market, followed by Europe. Increasing investments in the development of structure-based drug designs, growing academic and government investments in genomics and proteomics research, rising demand for high-quality research tools for data reproducibility, and rising focus of stakeholders on research projects involving proteins, associated biomolecules, and genes are the factors propelling the growth of the market in the region. Prominent players in the proteomics market are Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc.(US), GE Healthcare (US), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), Luminex Corporation (US), Bruker Corporation (US), Merck KGaA,(Germany), Waters Corporation (US), PerkinElmer, Inc. (US), Creative Proteomics (US), and Promega Corporation (US). |
February 2019 | $ 5650 |
|
Immunoprecipitation Market by Product (Kit, Reagent (Antibodies, Magnetic Buffer)), Type (Individual IP, Coimmunoprecipitation, CHIP), End User (Academics, Research Institutes, Pharmaceutical and Biotechnology Companies) - Global Forecast to 2024The market for immunoprecipitation is expected to grow from USD 560 million in 2018 to USD 750 million by 2024, at a CAGR of 5.0% during the forecast period. The growth of this market is majorly driven by the increasing research in the life sciences industry and the growing need to identify antigens associated with autoimmune diseases (through antigen-antibody interaction to understand disease mechanisms and develop relevant drugs targeting these diseases). The prominent players in the global immunoprecipitation market are Thermo Fisher Scientific (US), Abcam (UK), and Merck KGaA (Germany) |
February 2019 | $ 5650 |
|
Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services), Application (Cell Biology, Stem Cells, Drug Discovery), End User (Pharmaceutical & Biotechnology Companies, Research Institutes) - Global Forecasts to 2023The global live cell imaging market is expected to reach USD 2.9 billion by 2023 from an estimated USD 1.9 billion in 2018, at a CAGR of 8.9%. Growth in the live cell imaging market can primarily be attributed to various factors such as the growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research. The key players in the live cell imaging market are Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), and NanoEnTek Inc. (Korea). |
February 2019 | $ 5650 |
|
Filter Integrity Test Market by Test Type (Bubble Point, Diffusion, Water Flow), Mechanism (Manual, Automation), Filter Type (Air, Liquid), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, Academics) - Global Forecast to 2024The market for filter integrity test is projected to reach USD 79 million by 2024 from USD 59 million in 2018, at a CAGR of 5.0% during the forecast period. Factors such as increasing R&D spending, growth in the biopharmaceutical industry, and increasing purity requirements in the end-user market are driving the growth of the filter integrity test market. The major players in the filter integrity test market are Merck KGaA (Germany), Danaher Corporation/Pall Corporation (US), Sartorius (Germany), Donaldson Company (US), Parker Hannifin Corporation (US), Meissner Filtration Product (US), MDI Filtration Technologies (US), Thermo Fisher Scientific (US), Eaton Corporation (Ireland), and SH-Surway (China). |
February 2019 | $ 5650 |
|
Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents & Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Labs, Pharma-Biotech), Application, and Region - Global Forecast to 2023The flow cytometry market is projected to grow from an estimated USD 3.7 billion in 2018 to USD 5.4 billion by 2023, at a CAGR of 8.1% during the forecast period. Market growth is largely driven by factors such as technological advancements in flow cytometers, the increasing adoption of flow cytometry techniques in research activities and clinical trials, growing focus on immunology and immuno-oncology research, high incidence and prevalence of HIV-AIDS and cancer, and the increasing availability of novel application-specific flow cytometry products. The growing market penetration in emerging countries, growth in stem cell research, adoption of recombinant DNA technology for antibody production, and evolution of tandem flow cytometry technologies are expected to present a wide range of growth opportunities for market players. The major players operating in the flow cytometry market are Becton, Dickinson and Company (US), Beckman Coulter, Inc. (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Sysmex Partec GmbH (Germany), Luminex Corporation (US), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (US), Sony Biotechnology, Inc. (US), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Enzo Life Sciences, Inc. (US), Stratedigm, Inc. (US), Cytonome/ST LLC (US) and Apogee Flow Systems Ltd. (UK). |
January 2019 | $ 5650 |
|
Cell Therapy Technologies Market by Product (Consumables, Equipment, Software), Cell Type (Human Stem & Differentiated, Animal), Process Stages (Cell Processing, Distribution, Handling, QC), End User, and Region - Global Forecast to 2023The global cell therapy instruments market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4% during the forecast period. Rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are the key factors driving the growth of this market. China, India, Japan, Korea, and Brazil are emerging markets for cell therapy instruments. These markets boast comparatively lenient standards and government regulations as opposed to developed markets in North America and the EU, and thus offer significant growth potential for providers. However, the high cost of cell-based research and the low success rate is expected to restrain market growth to some extent during the forecast period.Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US). |
December 2018 | $ 5650 |
|
Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023The global custom antibody market is projected to reach USD 481 million by 2023 from USD 313 million in 2018, at a CAGR of 8.9%. The growth of this market is mainly driven by the increase in research activities in the life sciences industry, growing industry-academia collaborations, expanding antibody therapeutics pipeline, and the growing quality concerns over catalog antibodies that are driving the end users towards custom-made antibodies. |
December 2018 | $ 5650 |
|
Cell Surface Markers Market by Product (Antibody, PCR Array), Source (Mice, Rat), Cell Type (T cells, B cells, NK cell), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)), and End User (Hospitals) - Global Forecast to 2023The cell surface markers market is valued at an estimated USD 520 million in 2018 and is projected to reach USD 769 million by 2023, at a CAGR of 8.1% during the forecast period. Factors such as the increasing funding for life sciences research, high global prevalence of cancer, and growth in stem cell and neurobiology research are expected to drive the growth of this market in the coming years. |
December 2018 | $ 5650 |
|
Animal Genetics Market by Products & Services (Live Animals (Poultry, Porcine, Bovine, Canine) Genetic Material (Semen (Bovine, Porcine), Embryo (Bovine, Equine)) Genetic Testing (DNA Testing, DNA Typing, Genetic Disease Testing)) - Forecast to 2023The animal genetic market is projected to reach USD 5.8 billion by 2023 from USD 4.2 billion in 2018, at a CAGR of 6.5 % during the forecast period. The prominent players in the animal genetics market are Neogen Corporation (US), Genus (UK), URUS (US), EW Group (Germany), Groupe Grimaud (France), CRV Holding (Netherlands), Topigs Norsvin (Netherlands), Zoetis (US), Envigo (US), Hendrix Genetics (Netherlands), Animal Genetics (US), and vetGen (US). Collaborations, partnerships and agreements, and acquisitions are the major growth strategies adopted by these players to strengthen their position in the market. |
December 2018 | $ 5650 |
|
Bioburden Testing Market by Product (Consumables, Instrument (PCR, Microscope)), Test (Anerobic, Mold/Fungi, Aerobic, Spore), Application (Raw Material, Medical Devices, Sterility Testing), End User (Pharma, Biotechnology, CMO) - Global Forecast to 2023The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. Growth in this market can be attributed to factors such as the growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination. However, the high cost of enumeration instruments is expected to restrain market growth in the coming years. The bioburden testing market is competitive in nature, with the presence of several large and small players. Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific (US), biomérieux SA (France), and Pacific BioLabs (US) are some of the leading payers in the bioburden testing market. |
December 2018 | $ 5650 |
|
Synthetic Stem Cells Market by Application (Cardiovascular Disease, Neurological Disorders, Other Applications (Cancer, Diabetes, Gastrointestinal, Musculoskeletal Disorders)), Region (North America (US, Canada), Europe, APAC, RoW) - Global Forecast to 2028The market size for synthetic stem cells is expected to grow from USD 14 million in 2023 to USD 37 million by 2028, at a CAGR of 22.5% during the forecast period. The ethical concerns on the use of embryonic stem cells and the risk of tumor formation and immune response to natural stem cells are the key factors driving the growth of this market. The key developers of synthetic stem cell technology are North Carolina State University (NCSU) (US) and Zhengzhou University (China). |
December 2018 | $ 5650 |
|
Gel Documentation Systems Market by Product (Instruments (Digital), Software), Light Source (Laser, LED, UV), Detection (Chemiluminescence), Application (Nucleic Acid), End User (Academic Institutes, Biotechnology Companies) - Global Forecast to 2023The gel documentation systems market is projected to grow from USD 258 million in 2018 to USD 304 million by 2023, at a CAGR of 3.3% during the forecast period. Growth in the gel documentation systems market is mainly driven by the increasing prevalence of infectious and chronic disease, and rising research & development expenditure in the pharmaceutical and biotechnology companies. The major players in the gel documentation systems market are GE Healthcare (US), Bio-Rad Laboratories, inc. (US), Thermo Fisher Scientific (US), LI-COR Biosciences (US), Endress+Hauser Management AG (Switzerland), Vilber Lourmat (France), Scientific Digital Imaging plc (UK), Bio-Techne (US), Cleaver Scientific (US), and Azure Biosystems (US). |
December 2018 | $ 5650 |
|
Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023The global genotyping assay market is projected to reach USD 31.9 billion by 2023 from USD 11.8 billion in 2018, at a CAGR of 22.0%. The growth of this market is mainly driven by technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases. The prominent players in the genotyping market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US). |
November 2018 | $ 5650 |
|
Protein Sequencing Market by Product (Sample Preparation, MS, Sequencer, Reagent, Consumable), Service, Technology (MS, Edman), Application (Biotherapeutics, Genetic Engineering), Enduser (Academia, Pharma, Biotechnology, CROs) - Global Forecast to 2023The protein sequencing market is projected to grow from an estimated USD 925 million in 2018 to USD 1,088 million by 2023, at a CAGR of 3.3% during the forecast period. Growth in the protein sequencing market is mainly driven by the increasing focus on target-based drug development by pharmaceutical and biotechnology companies, advancements in clinical mass spectrometry and analytical techniques, and increasing public-private financial support for proteomic research. Some of the prominent players in the protein sequencing market include Shimadzu (Japan), Thermo Fisher Scientific Inc. (US), SGS S.A. (Switzerland), Waters Corporation (US), Rapid Novor (Canada), Agilent Technologies (US), Charles River Laboratories (US) and Selvita (Poland). |
November 2018 | $ 5650 |
|
CRISPR Technology Market by Product (Enzymes, Kits, gRNA, Libraries, Design Tools), Service (gRNA Design, Cell Line Engineering), Application (Biomedical, Agricultural), End User (Pharma & Biopharma Companies, Academics, CROs) - Global Forecast to 2023The market for CRISPR technology is expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period. The rise in the availability of government and private funding and the adoption of CRISPR technology are the key factors driving the growth of this market. Some of the key players of CRISPR in this region are Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US). |
November 2018 | $ 5650 |
|
Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) - Global Forecast to 2023The global apoptosis assays market is projected to reach USD 5.9 billion by 2023 from USD 3.6 billion in 2018, at a CAGR of 10.5%. The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US). |
November 2018 | $ 5650 |
|
Gene Expression Analysis Market by Product and Services (Consumables (Reagents, DNA chips), Instruments (PCR, NGS), Services (Gene Expression Profiling)), End User (Pharma and Biotech Companies, Research Centers) - Global Forecasts to 2023The market for gene expression analysis market is expected to grow from USD 3.2 billion in 2018 to USD 4.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 8.8% during the forecast period. The major players operating in the gene expression analysis market include Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are the key players in the gene expression analysis market. Other players involved in this market are F. Hoffmann-La Roche Ltd. (Switzerland), GE Healthcare (UK), Pacific Biosciences of California, Inc. (US), BGI (China), PerkinElmer (US), Agilent Technologies Inc. (US), and QIAGEN N. V. (Netherlands), among others. |
November 2018 | $ 5650 |
|
Desalting and Buffer Exchange Market by Product (Kit, Cassette & Cartridge, Spin Columns), Technique (Size Exclusion Chromatography, Filtration, Dialysis), Application (Bioprocess (Pharmaceutical Companies, Research Institutes)) - Global Forecast to 2023The global desalting and buffer exchange market is projected to reach USD 1,094.8 million by 2023 from USD 679.8 million in 2018, at a CAGR of 10.0%. The base year considered for the study is 2017, and the market forecast is provided for 2018–2023. Growth in this market will largely be driven by increasing demand for mAbs, increasing R&D expenditure by pharmaceutical and biopharmaceutical companies, and growing focus on proteomic and genomic research. Key players in the global desalting and buffer exchange market are Thermo Fisher Scientific (US), Merck (US), GE Healthcare (US), Danaher (US), and Sartorius (Germany). |
October 2018 | $ 5650 |
|
Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023The global viral clearance market is expected to reach USD 724.5 million by 2023 from an estimated USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period. The growth of this market is primarily driven by factors such as the growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and high incidence and large economic burden of chronic diseases. The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria). |
September 2018 | $ 5650 |
|
Bioinformatics Market by Product & Service (Knowledge Management Tools, Data Analysis Platforms (Structural & Functional), Services), Applications (Genomics, Proteomics & Metabolomics), & Sectors (Medical, Academics, Agriculture) - Global Forecast to 2023The global bioinformatics market is projected to reach USD 13.50 billion in 2023 from USD 7.73 billion in 2018, at CAGR of 14.5%. Growing demand for nucleic acid and protein sequencing and the rising applications of bioinformatics in drug discovery, clinical diagnostics, and personalized medicine are key factors supporting the growth of this market. On the other hand, a lack of well-defined standards and common formats for data integration may limit market growth to a certain extent. The bioinformatics market is highly competitive due to the presence of a large number of players. Few of the major companies in bioinformatics market are Thermo Fisher Scientific (US), Illumina Inc (US), Agilent Technologies (US), QIAGEN (Netherlands), BGI (China), Wuxi NextCODE (China), Eurofins Scientific (Luxembourg), Waters Corporation (US), Sophia Genetics (Switzerland), Partek (US), and DNASTAR (US). |
September 2018 | $ 5650 |
|
Hollow Fiber Filtration Market by Technique (Microfiltration, Ultrafiltration), Material (Polymer, Ceramic), Application (Harvest & Clarification, Concentration, Perfusion), End User (Pharmaceutical Manufacturer, CRO, CMO) - Global Forecast to 2023The global hollow fiber filtration market is projected to reach USD 517.4 million by 2023 from USD 274.7 million in 2018, at a CAGR of 13.5%. The growth of this market can be attributed to the rising preference for continuous manufacturing in the biopharmaceutical industry and the increasing demand for biopharmaceuticals. The hollow fiber filtration market is consolidated due to the presence of a few major players. Asahi Kasei Corporation (Japan), Repligen Corporation (US), GE Healthcare (US), Danaher Corporation (US), and Koch Membrane Systems (US) are the leading players in this market. |
September 2018 | $ 5650 |
|
Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023The global cell viability assays market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%. Factors contributing to the growth of this market include the rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research, rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics. The prominent players in the cell viability assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US). |
September 2018 | $ 5650 |
|
Track etched Membrane Market by Product (Membrane Filter, Capsule & Cartridge Filter, Cell Culture Insert), Material (Polycarbonate, Polyimide), Application (Cell Biology, Microbiology, Analytical testing, Automotive), End User - Global Forecast to 2023The track etched membrane market is expected to reach USD 813.1 million by 2023 from USD 476.0 million in 2018, at a CAGR of 11.3% from 2018 to 2023. Key factors driving the growth of this market include increasing R&D spending in the pharmaceutical and biopharmaceutical industries and increasing purity requirements among end users of track etched membranes. However, the high cost of production and the limited supply of track etched membranes are major factors that are expected to restrain the growth of this market during the forecast period. Key players operating in the global track etched membrane are GE Healthcare (US), Danaher (US), Corning (US), Merck (Germany), it4ip (Belgium), Sterlitech (US), Oxyphen (Switzerland), Sarstedt (US), BRAND GMBH (Germany), Sartorius (Germany), SABEU (Germany), Zefon International (US), GVS (Italy), Thermo Fisher Scientific (US), Eaton (Ireland), Greiner Bio-One (Austria), MACHEREY-NAGEL (Germany), Avanti Lipids Polar (US), SKC (US), Advantec (Canada), Avestin (Canada), Scaffdex (Finland), and Graver Technologies (US). |
September 2018 | $ 5650 |
|
Next-Generation Sequencing (NGS) Market by Product (NovaSeq, NextSeq, Sequel, Nanopore), Consumables, Bioinformatics, Services (Exome, RNA, DeNovo), Technology (Ion, SMRT), Application (Diagnostics, Cancer), End User (Academia) - Global Forecasts to 2024The global next-generation sequencing market is projected to reach USD 16.35 billion by 2024 from USD 5.70 billion in 2018, at a CAGR of 19.2% during the forecast period. Factors such as advancements in NGS platforms, declining NGS capital cost coupled with the decreasing cost of sequencing, and improving regulatory & reimbursement scenario for NGS-based diagnostic tests are expected to drive the growth of the next-generation sequencing market. Some of the prominent players in the next-generation sequencing market include Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Pacific Biosciences of California, Inc. (US), BGI (China), PerkinElmer (US), Agilent Technologies (US), QIAGEN N. V. (Germany), Macrogen Inc. (South Korea), Oxford Nanopore Technologies, Ltd. (UK), and Eurofins Scientific (Luxembourg). |
August 2018 | $ 5650 |
|
Hydrophobic Interaction Chromatography Market by Product & Services (Resin, Columns (Empty, Prepacked), Buffer), Sample (Monoclonal Antibodies, Vaccines), End User (Pharmaceutical Companies, CROs & CMOs, Research Institutes) - Global Forecast to 2023The global hydrophobic interaction chromatography market is projected to reach USD 418.2 million in 2023 from USD 271.0 million in 2017, at a CAGR of 7.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. In the current market scenario, there is a growing demand for hydrophobic interaction chromatography. The major factors driving the growth of this market are the increasing demand for monoclonal antibodies and increasing R&D expenditure in biopharmaceuticals. The key players in the global hydrophobic interaction chromatography market are GE Healthcare (US), Bio-Rad Laboratories (US), Sartorius (Germany), and Thermo Fisher Scientific (US). |
August 2018 | $ 5650 |
|
Protein Binding Assays Market by Technology (Equillibrium Dialysis, Ultrafiltration, Ultracentrifugation, Gel Filtration Chromatography), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organization) - Global Forecast to 2023The major players operating in the global protein binding assay market are Thermo Fisher (US), HTDialysis (US), Merck (US), GE Healthcare (US), and Absorption Systems (US). The global protein binding market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at a CAGR of 10.7%. The growing number of drug discovery activities, the minimizing drug discovery and development costs, and the increase in pharmaceutical R&D expenditure are driving the growth of this market. The key players in the global protein binding assays market are HTDialysis (US), Thermo Fisher Scientific (US), Merck (Germany), and Sovicell (Germany). |
August 2018 | $ 5650 |
|
Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type (DNA, Protein Microarray), Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies) - Global Forecast to 2023The global microarray analysis market is expected to reach USD 5.52 billion by 2023 from USD 3.82 billion in 2018, at a CAGR of 7.6%. The major factors driving the growth of this market are the increasing incidence of cancer, increasing funding for genomic and proteomic research, and growing application areas of microarrays. Key players in the microarray analysis market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Molecular Devices (US), PerkinElmer Inc. (US), Illumina, Inc. (US), GE Healthcare (US), and Bio-Rad Laboratories Inc. (US). |
August 2018 | $ 5650 |
|
Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0%. Some key factors driving market growth include the rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. Untapped potential in emerging markets is expected to offer lucrative growth opportunities for players in the viral vector manufacturing market. The major players in the global viral vector manufacturing market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), Kaneka Eurogentec (Japan), and Spark Therapeutics (US). |
August 2018 | $ 5650 |
|
Primary Cells Market by Type (Human Primary Cells, Animal Primary Cells), Origin (Hematopoietic, Blood, Skin, Gastrointestinal, Hepatocytes, Renal, Skeleton & Muscles), End User (Life Science Research & Research Institutes) - Global Forecast to 2023The global primary cells market is expected to reach USD 1,107.3 million by 2023 from USD 736.4 million in 2018, at a CAGR of 8.5%. Growth in the primary cells market is mainly driven by factors such as increasing cancer research; the advantages of primary human cells over cell lines; the increasing demand for monoclonal antibodies; rapid growth in the biotechnology and biopharmaceutical industries, partnerships, collaborations, and acquisitions; and increasing pharmaceutical outsourcing. Key players in the primary cells market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (US), PromoCell (Germany), ZenBio (US), STEMCELL Technologies (Canada), AllCells (US), American Type Culture Collection (US), and Axol Biosciences (UK). |
July 2018 | $ 5650 |
|
Cell Counting Market by Product (Instruments (Spectrophotometer, Cell Counter, Hemocytometer, Flow Cytometer, Hematology Analyzer), Consumables (Reagent, Assay Kits, Microplate)), End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2023The global cell counting market is projected to reach USD 12.32 billion by 2023 from USD 8.84 billion in 2018, at a CAGR of 6.8%. Factors contributing to the growth of this market include growing incidence of diseases and disorders, development of enhanced solutions and improved image analysis, and growing use of high-throughput flow cytometry and automated hematology analyzers. The prominent players in the global cell counting market are Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Agilent Technologies (US), BioTek Instruments (US), Tecan Group (Switzerland), Roche Diagnostics (Switzerland), Sysmex Corporation (Japan), HORIBA, Ltd. (Japan), Abbott Laboratories (US), and Siemens Healthineers (Germany). |
July 2018 | $ 5650 |
|
Aseptic Sampling Market by Type (Manual (Type (Traditional, Single use), Product (Bags, Bottles, Syringes, Accessories)), Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO) - Global Forecast to 2023The aseptic sampling market is expected to reach USD 1,247.0 million by 2023 from USD 583.3 million in 2017, at a CAGR of 13.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. The growth of this market is primarily driven by factors such as the increasing demand for biopharmaceuticals and the presence of stringent government regulations for ensuring drug safety. The major players operating in the market include Sartorius Stedim Biotech (France), Merck Millipore (Germany), Danaher (US), and Thermo Fisher Scientific (US). |
July 2018 | $ 5650 |
|
Peptide Synthesis Market by Product (Reagent, Synthesizer, Chromatography), Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), End User (Pharmaceuticals & Biotechnology, CRO), and Region - Global Forecast to 2023The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period. Factors such as the growing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to drive the growth of the market. However, the lack of a unified set of regulations for therapeutic peptides is expected to restrain the growth of this market during the forecast period. The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market. |
July 2018 | $ 5650 |
|
Microcarrier Market by Equipment (Bioreactor, Culture Vessels, Cell Counter, Filtration System), Consumables (Sera, Serum Free Media), Microcarriers (Cationic, Collagen, Protein coated), Application (Vaccines, Cell Therapy) - Global Forecast to 2023The microcarriers market is projected to reach USD 1.61 billion by 2023 from USD 1.20 billion in 2018, at a CAGR of 6.0%. Growth in this market is driven by the rising demand for cell-based vaccines, technological advancements, and the availability of public and private funding for cell-based research. On the other hand, factors such as the high cost of cell biology research and limitations in the production of high-density cell culture are likely to hinder market growth. The key players in the microcarriers market are Thermo Fisher Scientific (US), Merck KGaA (Germany), and GE Healthcare (US), Danaher Corporation (US), Corning Incorporated (US), Lonza (Switzerland), Becton, Dickinson and Company (US), Eppendorf AG (Germany), HiMedia Laboratories (India), and Sartorius AG (Germany). |
July 2018 | $ 5650 |
|
Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies) - Global Forecast to 2023The global transfer membrane market is expected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period. Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are expected to drive the growth of transfer membrane market. The key players in the transfer membrane market include Merck KGaA (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Pall Coporation (US), Advansta (US), GVS (Italy), Santa Cruz Biotechnology (US), Abcam (UK), ATTO Corporation (Japan), Carl Roth (Germany), Macherey-Nagel (Germany), Azure Biosystems (US), and Axiva Sichem Biotech (India), among others. |
June 2018 | $ 5650 |
|
Nucleic Acid Isolation and Purification Market by Product (Reagent, Kit, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid, miRNA), Application (Precision Medicine), End User (Hospitals, Research Center) - Global Forecast to 2023The global nucleic acid isolation and purification market is expected to reach USD 4.38 billion by 2023 from USD 2.77 billion in 2018, at a CAGR of 9.6%. The major factors driving the growth of the market include increasing public-private funding for life science research, technological advancements, and increasing automation. However, the high cost of automated instruments is expected to hinder the growth of the market. The nucleic acid isolation and purification market is highly consolidated with few major companies holding a majority of the market share. In 2018, QIAGEN (Netherlands), Thermo Fisher Scientific (US), and Roche (Switzerland) are expected to dominate the nucleic acid isolation and purification market. Other prominent players in this market include Merck KGaA (Germany), Agilent Technologies (US), Illumina (US), Takara Bio (Japan), Promega Corporation (US), GE Company (US), Danaher Corporation (US), New England Biolabs (US), and Bio-Rad Laboratories (US). |
June 2018 | $ 5650 |
|
Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecast to 2023The global creatinine measurement market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%. The growth of this market is mainly driven by increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and increasing number of drug development initiatives. The creatinine measurement market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include F. Hoffmann-la Roche Ltd (Switzerland)., Abbott Laboratories (US), Danaher Corporation (US), Thermo Fisher Scientific Inc (US), Siemens Healthineers (Germany), Randox Laboratories (UK)., Pointe Scientific, Inc (US), Sentinel Ch. Spa. (Italy), Diasys Diagnostic Systems GmbH (Germany), Dialab GmbH (Vienna), Diazyme Laboratories, Inc (US), Wako Pure Chemical Industries, Ltd. (Japan), Ortho Clinical Diagnostics (US), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China). |
June 2018 | $ 5650 |
|
Multiplex Assays Market by Product (Consumables, Instruments), Type (Nucleic Acid, Protein, Cell), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma & Biotech, Reference Laboratory, Hospital) - Global Forecast to 2023The global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.33 Billion in 2018, at CAGR of 7.5%. Multiplex assays enables the simultaneous detection of multiple analytes in a single run/cycle of the assay. The use of multiplex assays in companion diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays are driving the growth of the market. The key players in the global multiplex assays market are Luminex (US), Bio-Rad Laboratories (US), Becton Dickinson (US), Illumina (US), and Thermo Fisher Scientific (US). |
June 2018 | $ 5650 |
|
Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), Application (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical Companies) - Global Forecast to 2023The global gene panel market is expected to reach USD 2.95 Billion by 2023 from USD 1.22 Billion in 2018, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market. |
May 2018 | $ 5650 |
|
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers. |
May 2018 | $ 5650 |
|
Neuroscience Antibodies & Assays Market by Product (Reagent (Media, Sera, Stain, Enzymes, Probe), Instruments), Technology (Immunoassay (Elisa), Molecular Diagnostics), Application (IVD) & End User (Research Institute, Hospital) - Global Forecast to 2023The global neuroscience antibodies and assays market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%. Growth in this market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries. The neuroscience antibodies and assays market is fragmented, with the presence of several large as well as emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the neuroscience antibodies and assays market. Other major players include BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), GenScript (China), Rockland Immunochemicals (US), Santa Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland). |
May 2018 | $ 5650 |
|
Stem Cell Banking Market by Source (PSC, BMSC, ADSC, hESC, DPSC, NSC), Service Type (Sample Processing, Analysis, Collection, Storage), Application (Personalized Storage, Clinical (Autoimmune, Hematopoietic Disorders), Research) - Global Forecasts to 2023The global stem cell banking market is projected to reach USD 9.30 Billion by 2023 from USD 6.28 Billion in 2018, at a CAGR of 8.2%. Factors such as public awareness related to the therapeutic potential of stem cells; development of novel technologies for stem cell preservation, processing, and storage; rising number of hematopoietic stem cell transplantations (HSCTs); and increasing number of stem cell-based research are driving the growth of the market. As of 2017, major players in the global stem cell banking market include Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico). |
May 2018 | $ 5650 |
|
Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022The global human liver models market is projected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6%. The growth of this market is primarily driven by factors such as the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure. The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan). |
April 2018 | $ 5650 |
|
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.
Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement
Connect With Us
Live Chat Support
Search reports
Biotechnology ›
Information and Communications Technology ›
Semiconductor and Electronics ›
Medical Devices ›
Chemicals ›
Advanced Materials ›
Energy and Power ›
Food and Beverage ›
Aerospace and Defence ›
Healthcare IT ›
Automotive and Transportation ›
Automation and Process Control ›
Agriculture Industry ›
Packaging ›
Pharmaceuticals ›
Building and Construction ›
Mining, Minerals and Metals ›
Analytical and Scientific Instrumentation ›
Engineering Equipment and Devices ›
'Connect With Us
